Evaluation with MIB1 antibody of proliferative activity in ovarian clear cell adenocarcinoma.
The purpose of this study was to determine whether proliferative activity is a prognostic factor in ovarian clear cell adenocarcinoma. The paraffin-embedded sections from eight cases of ovarian clear cell adenocarcinoma were immunostained with monoclonal antibody MIB1 using microwave oven heating for antigen retrieval. The difference in survival (Kaplan-Meier) between patients with high and low MIB1 expression was estimated with the generalized Wilcoxon test. MIB1 positivity ranged from 1.80 to 27.12% with a mean of 11.43%. A cutoff point of 10% dichotomized patients into two groups. The survival of high (> or = 10%) expressing tumors was worse than that of low (< 10%) expressing tumors (p < 0.05). MIB1 immunostaining may have useful prognostic value in ovarian clear cell adenocarcinoma.
Morimura
Y
Y
Department of Obstetrics and Gynecology, Fukushima Medical College, Japan.
Hoshi
K
K
Hang
X L
XL
Takano
Y
Y
Ohishi
M
M
Honda
T
T
Yamada
H
H
Sato
A
A
D018262:Adenocarcinoma, Clear Cell / Q000473:pathology*; D000328:Adult; D000911:Antibodies, Monoclonal; D002455:Cell Division; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D008938:Mitosis; D010051:Ovarian Neoplasms / Q000473:pathology*; D011379:Prognosis; D015203:Reproducibility of Results
D000911:Antibodies, Monoclonal